蒲公英 - 制药技术的传播者 GMP理论的实践者

搜索
查看: 1202|回复: 2
收起左侧

Glenmark 投$17 million 在北卡罗来纳州做生物制品

[复制链接]
药生
发表于 2014-8-6 11:05:29 | 显示全部楼层 |阅读模式

欢迎您注册蒲公英

您需要 登录 才可以下载或查看,没有帐号?立即注册

x
还是一则英语新闻:

$17 mGlenmark to invest $17 million in production facilities in North Carolina
City, county and state chipped in $1M to entice the Indian drugmaker

August 4, 2014 | By Eric Palmer
When India's Glenmark Pharmaceuticals said two weeks ago that it had decided on Union, NC, for its first production operation in North America, it didn't say just how much the company intended to invest. It turns out the plant is expected to cost more than $15 million and that taxpayers in the state will ante up a sizable chunk of that.
The Indian drugmaker announced July 17 that its first U.S. facility would include three units spread over 100,000 square feet to manufacture solids, injectables and topicals, with the facility for solids being up first. It expects the construction of all three units to be complete within 5 years.
"The U.S. is a key strategic market for Glenmark and it is important for us to have a manufacturing base here to serve our growing business in the country," Glenn Saldanha, Glenmark chairman, said in a statement. Glenmark currently does about $65 million worth of business in the U.S.
According to the Charlotte Observer, Glenmark is investing about $17 million in the new facility but will get about $1 million in a grab bag of incentives from the city, county and state to help it cover some costs. For example, the city is selling the drugmaker a 102,000-square-foot building for $2.96 million, a $625,500 discount on its $3.58 million appraised value.
The county is making a $340,000 grant over 5 years, while the state will provide about $61,500 for college training for workers. In return, the company pledged at least 41 jobs in the first three years. An economic development official said the deal was negotiated in 5 weeks, the fastest he has seen a deal coalesce in his 20 years of eco-devo work.
The company already had 14 manufacturing facilities in India, Brazil, Argentina and the Czech Republic and recently opened a mAb manufacturing facility in Switzerland to feed its pipeline of monoclonal antibodies and biosimilars.

回复

使用道具 举报

药徒
发表于 2014-8-6 11:16:01 | 显示全部楼层
{:soso_e109:}
我要学英语……
回复

使用道具 举报

药徒
发表于 2014-8-6 11:48:17 | 显示全部楼层
回复

使用道具 举报

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

×发帖声明
1、本站为技术交流论坛,发帖的内容具有互动属性。您在本站发布的内容:
①在无人回复的情况下,可以通过自助删帖功能随时删除(自助删帖功能关闭期间,可以联系管理员微信:8542508 处理。)
②在有人回复和讨论的情况下,主题帖和回复内容已构成一个不可分割的整体,您将不能直接删除该帖。
2、禁止发布任何涉政、涉黄赌毒及其他违反国家相关法律、法规、及本站版规的内容,详情请参阅《蒲公英论坛总版规》。
3、您在本站发表、转载的任何作品仅代表您个人观点,不代表本站观点。不要盗用有版权要求的作品,转贴请注明来源,否则文责自负。
4、请认真阅读上述条款,您发帖即代表接受上述条款。

QQ|手机版|蒲公英|ouryao|蒲公英 ( 京ICP备14042168号-1 )  增值电信业务经营许可证编号:京B2-20243455  互联网药品信息服务资格证书编号:(京)-非经营性-2024-0033

GMT+8, 2025-4-11 07:19

Powered by Discuz! X3.4运维单位:苏州豚鼠科技有限公司

Copyright © 2001-2020, Tencent Cloud.

声明:蒲公英网站所涉及的原创文章、文字内容、视频图片及首发资料,版权归作者及蒲公英网站所有,转载要在显著位置标明来源“蒲公英”;禁止任何形式的商业用途。违反上述声明的,本站及作者将追究法律责任。
快速回复 返回顶部 返回列表